Pembrolizumab plus chemotherapy for pleural mesothelioma

Lancet. 2023 Dec 16;402(10419):2266-2267. doi: 10.1016/S0140-6736(23)01883-4. Epub 2023 Nov 3.

Author

Affiliation

¹ Pleural Medicine Unit, Institute for Respiratory Health, Perth, WA 6009, Australia; School of Medicine, University of Western Australia, Perth, WA, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia. Electronic address: gary.lee@uwa.edu.au.

PMID: 37931626
DOI: 10.1016/S0140-6736(23)01883-4

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin / therapeutic use
Humans
Lung Neoplasms* / drug therapy
Mesothelioma* / drug therapy
Mesothelioma, Malignant* / drug therapy
Pemetrexed / therapeutic use
Pleural Neoplasms* / drug therapy

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
Cisplatin
Pemetrexed